What are findings from the Cardiomyopathy Trial (CAT) regarding implantable cardioverter-defibrillators (ICD) therapy?

Updated: Oct 11, 2019
  • Author: Daniel M Beyerbach, MD, PhD; Chief Editor: Jeffrey N Rottman, MD  more...
  • Print


The Cardiomyopathy Trial (CAT), in which 104 subjects with recent (< 9 mo) onset of nonischemic cardiomyopathy were randomized to ICD therapy or control group, was terminated early, at 1 year, due to lower than expected mortality in the control group (3.7% vs the expected 30%). At a mean follow-up of 5.5 years, no significant difference was shown in cumulative survival. [26]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!